<DOC>
	<DOCNO>NCT00798590</DOCNO>
	<brief_summary>The goal present proposal examine efficacy GLP-1 administer control blood glucose critically ill patient .</brief_summary>
	<brief_title>The Efficacy GLP - 1 ( 7-36 ) Amide Glycemic Control Critically Ill Patients</brief_title>
	<detailed_description>All patient admission ICU ( surgical , burn , &amp; cardiac ) expect receive intensive insulin therapy least 72 hour eligible enrol . Once enrolled , patient randomize one two group : experimental ( intravenous GLP-1 infusion 72 hour ) control group ( intravenous 0.9 % NaCl infusion 72 hour ) double masked fashion . While enrolled , patient receive standard-of-care insulin therapy . Both group maintain standard ICU specific protocol glucose control .</detailed_description>
	<mesh_term>Critical Illness</mesh_term>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Men woman age &gt; 21 75 year age . All subject meet ICU specific criterion inclusion glucose protocol place insulin infusion protocol standard care . Able obtain patient proxy consent . Current diagnosis malignancy . Type 1 diabetes . Inability obtain informed consent . On Phase 1 trial .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Intensive insulin therapy ( IIT )</keyword>
	<keyword>Insulin infusion</keyword>
	<keyword>Tight glycemic control</keyword>
	<keyword>Intensive Care Units</keyword>
</DOC>